Testing for Sickle Cell Disease: From a Screening Result to a Confirmed Diagnosis

A report stating that hemoglobin S, or HbS, was detected can raise questions in someone who has never felt unwell, or begin an important care pathway for a newborn. The finding needs interpretation. It does not, by itself, establish how severe a person's condition is. Testing should clarify whether HbS is present, whether the person has disease or trait, whether another hemoglobin variant is involved, and whether recent treatment affects the result.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

An abnormal newborn screen, unexplained recurrent pain, anemia with jaundice, painful swelling of a child's hands and feet, or a family history of a hemoglobin disorder can prompt investigation. Some people are tested while planning pregnancy or because another blood test raises a question. No known family history does not exclude sickle cell disease: relatives may not know they are carriers. Genetic status should not be assumed from ethnicity or nationality. [S29]
Hemoglobin analysis and clinical information resolve many cases. Targeted genetic testing may help when findings are unclear, tests disagree, or a compound inherited state needs clarification. It also informs family and reproductive counseling. Not everyone needs whole-exome or whole-genome sequencing as the first step. The appropriate scope depends on the question rather than on which test examines the largest amount of DNA. [S1][S29]
Fever, chest symptoms, difficulty breathing, marked weakness, or new neurologic changes require medical attention even if genetic testing is unfinished. Clinicians can manage risk using the information already available. An unresolved subtype does not mean a person cannot have an acute complication. Preventive follow-up after an abnormal infant screen should also proceed as directed rather than wait for every document to be complete. [S24][S9]

Quick answer

Full guide

Recognize the different reasons for testing

An abnormal newborn screen, unexplained recurrent pain, anemia with jaundice, painful swelling of a child's hands and feet, or a family history of a hemoglobin disorder can prompt investigation. Some people are tested while planning pregnancy or because another blood test raises a question. No known family history does not exclude sickle cell disease: relatives may not know they are carriers. Genetic status should not be assumed from ethnicity or nationality. [S29]

An adult who cannot recall a newborn result can try to obtain the record. If it is unavailable, testing can establish current diagnostic information. Years without obvious symptoms do not answer every inheritance question, particularly when a reproductive partner may carry another hemoglobin variant. Explain whether the purpose is investigation of symptoms, clarification of a previous report, or reproductive counseling so the clinician can choose an appropriate approach. [S22][S34]

Understand the role of the blood count

A complete blood count identifies anemia and provides red-cell measurements that help guide further investigation. Reticulocytes show the marrow's response in producing new red cells, and a blood film shows their appearance. Together with the clinical history, these findings help assess possibilities such as hemolysis, iron deficiency, or thalassemia. A low cell-volume measurement or an unusual cell shape alone does not fully establish a sickle cell genotype. [S30]

Some carriers have normal counts, and the degree of anemia varies between disease types and individuals. A nearly normal hemoglobin concentration should not cancel indicated hemoglobin testing. Conversely, anemia is common to many conditions and does not automatically mean sickle cell disease. If iron studies are requested, the purpose is to examine possible iron deficiency or another contributing problem, not to assume that every anemic patient should take iron.

Bring previous counts when available. Knowing whether a result is typical for you or a sudden change helps the clinician interpret symptoms. A laboratory reference range is not the whole clinical assessment. Someone becoming much more unwell than usual may require prompt evaluation even if the exact hemoglobin-disorder classification is not yet complete.

Learn what hemoglobin analysis measures

Methods such as high-performance liquid chromatography, capillary electrophoresis, and isoelectric focusing help identify and quantify hemoglobin components. Reports may list HbA, HbF, HbS, HbC, and HbA2. The combination, relative amounts, age, and other findings are interpreted together. The presence of the letter S is not the complete answer. Laboratories may use another method to investigate an uncertain pattern because different variants can sometimes appear similar. [S1][S33]

If a report says “consistent with” a particular condition, ask how certain that conclusion is and what remains to be resolved. A further test should have a specific purpose. Laboratories use different platforms and reporting conventions, so retain the complete document, including its interpretation. Copying a percentage into a message and discarding the rest may remove the information the next clinician needs to make sense of it.

A screening result may need confirmation

Some rapid methods detect HbS but cannot adequately distinguish trait from disease or identify all other relevant components. The sickle solubility test is an example that cannot independently make this distinction. Low HbS concentrations and testing in young infants can also create limitations. A negative result from a limited method should not be used to dismiss every clinical concern. [S30]

Screening is useful when it leads promptly to confirmation and care. If a newborn program has reported a possible disease result, follow the recommended referral even if a second simple test elsewhere seems different. The team should compare sampling dates, methods, and treatment history before deciding what the disagreement means. Canceling follow-up without that review can leave an important question unresolved. [S31]

Ask which service will explain the confirmatory result. Families sometimes receive a laboratory notification without knowing whether the screening team, pediatrician, or specialist will make contact. A named appointment and an accurate phone number help close that gap. Keep a record of calls and documents received, particularly when screening and specialist care are provided by separate institutions.

Where standard hemoglobin fractionation or DNA testing is unavailable, the WHO's 2026 guideline conditionally supports evaluated lateral flow immunoassays or micro-engineered hemoglobin electrophoresis for diagnosis in children and adolescents, enabling prompt care. These are different from a solubility test that only indicates HbS. The recommendation does not make every rapid kit equivalent: identify the actual method and the local diagnostic and follow-up pathway. [S41]

Newborn results are age dependent

Fetal hemoglobin predominates around birth and changes as the infant grows. Adult reference proportions cannot simply be applied to a newborn. Letter patterns on screening reports often reflect relative quantities, but their meaning depends on the screening program and the baby's circumstances. Prematurity, sampling time, and other factors may affect interpretation. Confirmation should not be delayed until the baby becomes visibly anemic or has a pain episode. [S1][S33]

The purpose of early identification is to begin appropriate preventive care and monitoring. Feeding and sleeping normally do not prove that the result is false; many affected babies have no obvious symptoms at birth. Keep the sampling date, follow-up contact, and next appointment together. If the family moves during this period, make sure the screening result reaches the new clinician rather than assuming it will transfer automatically. [S9]

Tell the laboratory about transfusion

Donor red cells can alter the hemoglobin pattern after transfusion. HbA and HbS proportions following simple or exchange transfusion may differ substantially from the person's untreated pattern. This does not mean disease has suddenly become trait or disappeared. Give the clinician the latest transfusion date, method, and any available pretransfusion results, along with the longer transfusion history. [S5][S30]

If a newborn was transfused before screening, some programs use DNA testing to supplement the evaluation. The test still has a defined scope and may not identify every non-HbS variant. The specialist laboratory should determine whether later protein testing is required and when it will be interpretable. The goal is accurate documentation, not refusing an urgently needed transfusion to preserve a diagnostic sample. [S31]

When arranging a second opinion, mark which reports were obtained before and after transfusion. Sending every result without this distinction can make an understandable change look contradictory. A brief dated note can be enough to orient the reviewer, while the full documents remain available for detailed assessment.

Genetic testing should answer a specific question

Hemoglobin analysis and clinical information resolve many cases. Targeted genetic testing may help when findings are unclear, tests disagree, or a compound inherited state needs clarification. It also informs family and reproductive counseling. Not everyone needs whole-exome or whole-genome sequencing as the first step. The appropriate scope depends on the question rather than on which test examines the largest amount of DNA. [S1][S29]

Before testing, ask which variants or types of changes the laboratory can detect, what a negative result would exclude, and which possibilities might remain. A variant of uncertain significance should not be independently treated as proof of the diagnosis. If testing was performed abroad, retain the exact variant description and laboratory interpretation. A short translation containing only a disease name may be insufficient for specialist review.

The interpretation should also distinguish a diagnostic finding from a prediction of future severity. Even when the genotype is clear, the full clinical course cannot be read from a single result. Ask which parts of the report affect immediate care, which inform family counseling, and which require further discussion as the patient grows or develops new health needs.

Baseline health assessment is a different task

Once sickle cell disease is confirmed, further tests establish the starting point for care. Usual blood counts, kidney function, urine findings, symptoms, and complication history help plan treatment and follow-up. Red-cell antigen and antibody information is relevant to selecting compatible blood when transfusion is needed. These investigations are not merely repeating the question of whether the disease exists. [S5][S7]

Some children need transcranial Doppler screening according to age and genotype; brain MRI or cognitive evaluation may be considered in appropriate groups. Other monitoring, including eye assessment, is individualized. Not every test needs to occur on the day of diagnosis, but the family should know the order of priorities and which result might change near-term care. [S6]

If a recommended test is not available locally, ask the clinician whether it can be performed elsewhere and how the result will be reviewed. A list of investigations without follow-up responsibility is incomplete. This is particularly relevant when an international consultation suggests tests that the home system organizes differently.

Bone marrow biopsy and whole-body CT are not usual diagnostic requirements

Sickle cell disease is ordinarily diagnosed through blood hemoglobin analysis and genetic testing when needed. Bone marrow biopsy is not the routine way to identify the sickle variant, and whole-body CT does not assign the disease a cancer-style stage. If these investigations are proposed, ask whether there is a separate suspected condition or a specific complication to evaluate. The result should have a clear potential effect on management. [S1][S29]

The cost or apparent sophistication of an investigation does not establish its value. Suitable methods, correct sampling context, and skilled interpretation matter more than the number of tests ordered. A second opinion may reasonably repeat some testing, but the reason should be explained. Original records can sometimes resolve an uncertainty that otherwise would lead to another procedure.

Consider family and partner testing

After diagnosis, parents, siblings, or a reproductive partner may benefit from targeted testing and genetic counseling. The choice depends on known family variants and the question being asked. When both parents have sickle cell trait, each pregnancy has a one-in-four chance of sickle cell disease. This is a probability for each pregnancy, not a rule that exactly one of four children must be affected. [S34]

A partner carrying HbC or a beta-thalassemia variant can create a different inherited combination, so asking only whether the partner “has sickle cell disease” is incomplete. Counseling should explain the results, reproductive testing options, and their limitations without imposing a decision on the family. A screening label should not be used to judge whether someone should marry or become a parent. [S22][S18]

Keep copies of relevant family results rather than relying only on remembered labels. If relatives prefer not to share a full report, the genetics service can advise what information is necessary. The patient should understand why another person's result is being requested and how it relates to their own diagnostic or reproductive question.

Prepare for evaluation in China

Submit complete blood counts and reticulocytes, hemoglobin analysis, genetic reports, newborn screening results if available, transfusion dates, and current medicines. Distinguish documented family diagnoses from information recalled by relatives. If transplantation or gene therapy has already occurred, provide that history because subsequent blood results must be interpreted in its context. [S3]

Ask whether the receiving hospital can perform and interpret the required tests, whether specimens are analyzed on site or sent elsewhere, and who will discuss the results. A diagnostic appointment does not automatically require admission or a prolonged stay. Turnaround times and charges should come from the actual laboratory or hospital; this review has not established a single Chinese price or completion time that applies to all patients.

If results will become available after you leave, agree how they will be delivered and which clinician will act on them. A report arriving in a patient portal is not the same as an explanation. Your home physician may need both the original report and a clear summary of the conclusion so that the findings can guide ongoing care.

Do not leave symptoms untreated while waiting

Fever, chest symptoms, difficulty breathing, marked weakness, or new neurologic changes require medical attention even if genetic testing is unfinished. Clinicians can manage risk using the information already available. An unresolved subtype does not mean a person cannot have an acute complication. Preventive follow-up after an abnormal infant screen should also proceed as directed rather than wait for every document to be complete. [S24][S9]

At the end of the diagnostic process, ask for a plain-language conclusion: the established disease or carrier state, the evidence supporting it, any remaining uncertainty, and the next action. Save that explanation with the full results. It may be needed in an emergency, before transfusion, during pregnancy planning, or when changing hospitals. Good testing turns laboratory findings into an understandable care plan.